CLINICAL RESEARCH IN STEM CELL TRANSPLANTATION

干细胞移植的临床研究

• 批准号: 6660800
• 负责人: SCOTT I BEARMAN
• 金额: $ 12.55万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-09-14 至 2003-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6660800
• 关键词: autologous transplantation; breast neoplasms; carmustine; cis platinum compound; clinical research; clinical trial phase I; clinical trial phase II; cyclophosphamide; homologous transplantation; human subject; human therapy evaluation; metastasis; neoplasm /cancer chemotherapy; neoplasm /cancer immunotherapy; patient oriented research; radionuclides; stem cell transplantation; yttrium

The ongoing work and the proposed studies described in this application have, as a common theme, the use of immunotherapy as an adjunct to high-dose chemotherapy for patients with advanced or high-risk primary breast cancer. Three feasibility studies are described which form the basis for the proposed clinical trials, two of which are phase II and one of which is a randomized study. A retrospective analysis performed by Dr. Bearman's fellow, Dr. Yago Nieto, has resulted in the development of a model to predict patients with high-risk primary breast cancer who are at high-risk of relapse after autologous transplant. That model will identify candidates for two of the proposed clinical trials. This application also describes how Dr. Bearman will trainee young investigators in patient-oriented research. The UCHSC Bone Marrow Transplant Program has sufficient patients to conduct these studies, actively conducts both laboratory and clinical research, and is funded by both peer-reviewed and pharmaceutical support. Dr. Bearman will devote 50 percent effort to this 5 year program.

正在进行的工作和本文件中描述的拟议研究 作为一个共同的主题，应用免疫疗法作为 晚期或高危乳房患者的大剂量化疗 癌症。描述了三项可行性研究，这些研究构成了 拟议的临床试验，其中两项是II期，一项是A期 随机研究。贝尔曼博士的同事进行了一项回溯性分析， Yago Nieto博士开发了一种预测患者的模型 患有高危原发乳腺癌且术后复发风险高的患者 自体移植。该模型将确定以下两个项目的候选人 拟议的临床试验。这个应用程序还描述了贝尔曼博士如何 将培训年轻的研究人员进行以患者为导向的研究。UCHSC骨 骨髓移植项目有足够的患者来进行这些研究， 积极开展实验室和临床研究，并由两者资助 同行评议和药物支持。比尔曼博士将投入50% 为这个五年计划而努力。